|Bid||63.99 x 1100|
|Ask||64.01 x 800|
|Day's Range||63.02 - 64.80|
|52 Week Range||43.11 - 72.61|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||1,776.39|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||73.50|
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it received its latest U.S. Food and Drug Administration 510(k) clearance for the Pulse® platform, after receiving CE certification earlier this summer. In addition, the Company announced the commercial launch of Pulse which is now available for sale in targeted global regions.
NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.
Joining me today are Chris Barry, Chief Executive Officer; and Matt Harbaugh, Chief Financial Officer. Chris will provide an overview of NuVasive's recent business results and trends, and Matt will review our detailed financial results as well as the company's 2021 financial guidance.